Teva moves to independence in Japan as it buys out Kowa joint venture
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries is paying $150 million to acquire the 50% of its Japanese generics joint venture with Kowa that it does not already own, in a further expansion of the Israeli group's interests in this steadily growing market.